Search - tctmd.com

Displaying 1 - 20 of 316

Sort: Relevancy | Date

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

News Daily News

COVID-19: TCTMD’s Daily Dispatch for June Week 1

Todd Neale

June 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

Advertisement

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Top General Cardiology and CVD Prevention News of 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

LDL Control Remains Poor in CAD Patients: NHANES

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

COVID-19: TCTMD’s Daily Dispatch for June Week 1

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content